RLAY vs RXRX
RLAY and RXRX side by side — valuation & fundamentals (public data).
Key statistics
| Metric | RLAYRelay Therapeutics, Inc. | RXRXRECURSION PHARMACEUTICALS, INC. |
|---|---|---|
| Market cap | $3.78B | $2.38B |
| P/S | 250.4x | 33.2x |
| Revenue growth (YoY) | 53.4% | 26.9% |
| Earnings growth (YoY) | 18.1% | -39.1% |
| EBIT margin | -1971.6% | -867.9% |
| ROE | -31.1% | -71.2% |
| ROIC | — | -181.7% |
| 1y total return | +146.1% | -27.5% |
Figures from SEC filings · for reference only · not investment advice
Growth of $10,000: RLAY vs RXRX
| Metric | RLAY | RXRX |
|---|---|---|
| End value | $5.3K | $1.2K |
| Total return | -47.0% | -87.8% |
| CAGR | -10.8% | -31.5% |
| Volatility | 76.1% | 93.0% |
| Sharpe | 0.17 | -0.01 |
| Sortino | 0.26 | -0.02 |
| Max drawdown | -94.7% | -93.1% |
Based on 1394 common trading days, 2021-04-16 → 2026-11-02 · risk-free 4.16% (current short-Treasury, held constant)
A head-to-head total-return backtest over real split- and dividend-adjusted prices: how a one-time $10,000 investment in each stock, held to today, would have grown over their common window — including reinvested dividends. A disclosed historical statistic — NOT a prediction, a guarantee, or investment advice. Past performance does not predict future results.
Related comparisons
Delayed data · Public sources · For reference only · Not investment advice (this page declares no winner)